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Background: Infectious agents are estimated to play a causative role in approximately 20% of cancers worldwide.
Viruses, notably the Epstein-Barr virus (EBV), are associated with 10-15% of B-cell lymphomas and are found at a
higher frequency in immunosuppressed patients. In this study, we screened human lymphoma tissues using a novel
Lawrence Livermore Microbial Detection Array (LLMDA), a comprehensive detection system that contains probes for
all sequenced viruses and bacteria. This technology has been applied to identify pathogen-associated diseases.
Results: We evaluated samples from 58 cases with various lymphoid tissue disorders using LLMDA. These included
30 B-cell lymphomas (9 indolent and 21 aggressive type), 2 T-cell lymphomas and 2 NK/T cell lymphomas,
4 plasmacytomas as well as 8 specimens of benign lymphoid tissue. Five of 21 high-grade B-cell lymphomas
were positive for Epstein-Barr virus-encoded small RNA (EBER+), while all the indolent B-cell lymphomas were
EBER-. Similarly, both NK/T cell lymphomas were EBER+, and the benign tissues were EBER-. We also screened
10 cases of post-transplant lymphoproliferative disorder (PTLD). Five of these cases (4 B-cell lymphomas and 1
NK/T cell lymphoma) were EBER+, and the remaining five cases were EBER-.
Conclusions: We have confirmed the reliability of the LLMDA methods by detecting EBV in EBV-positive
lymphomas while observing no false-positive results in EBV-negative lymphomas. The LLMDA technique
provides a sensitive and alternative method for identifying known viral pathogen associated with tumors
and may prove useful for future clinical identification of novel cancer-associated viral pathogens.
Keywords: Epstein-Barr virus (EBV), Lymphoma, Post-transplant lymphoproliferative disorder (PTLD), Lawrence
Livermore Microbial Detection Array (LLMDA)Background
Infection associated cancers are on the rise worldwide
due to shifting pathogen habitats, a more interconnected
world and most importantly an aging population with a
longer life-expectancy [1,2]. As humans age, the immune
systems become dysregulated due to immunosenescence
leaving them more susceptible to infection (comorbidi-
ties and environmental exposures) [3-5]. It is estimated
that at least 20% of the global cancer incidence is caused
by infectious agents, with 10-15% of those caused by
viruses [6]. Over the past three decades, research has* Correspondence: mingyi.chen@ucdmc.ucdavis.edu
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unless otherwise stated.linked a number of cancers to infectious agents includ-
ing viruses (Epstein-Barr virus (EBV), human papilloma
virus (HPV), hepatitis B, human T-lymphotropic retro-
virus, Kaposi’s sarcoma-associated herpesvirus (KSHV),
and Merkel cell virus), bacteria (Helicobacter pylori),
and parasites (Schistosoma haematobium, Clonorchis
sinesis) [7]. Over 90% of the world’s population is in-
fected with EBV [8]. The organ transplant patients are
prone to viral infections due to immunosuppression
which leaving them susceptible to post-transplant lym-
phoproliferative disorder (PTLD) [9]. Immunocompetent
individuals control EBV infection with EBV-specific cyto-
toxic T lymphocytes (CTLs), while immunosuppressed
transplant patients lack CTLs and allow EBV propagation
that may lead to PTLD [8].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mon viruses affecting humans. EBV is an episomal, double-
stranded DNA virus that was discovered in a Burkitt
lymphoma cell line by Epstein et al. [10-12]. EBV’s pro-
miscuous tropism permits infection of a number of differ-
ent cell types including B-cells, T-cells, NK-cells and
epithelial cells [13-15]. Subsequently, EBV was found
to be associated with various human malignancies, includ-
ing nasopharyngeal carcinomas, PTLD, AIDS-associated
lymphomas, T cell lymphomas, NK cell lymphomas and
Hodgkin’s disease [11]. Importantly, EBV has been shown
to induce B cell transformation [11]. EBV-positive lymph-
omas can be divided into those occurring in immunodefi-
cient individuals, which are virally driven lymphomas,
such as PTLD and HIV-associated plasmablastic lymph-
oma (PBL), and those occurring in immunocompetent in-
dividuals. The latter group includes endemic and sporadic
Burkitt lymphoma, and some T-and NK-cell malignancies.
In the malignancies occurring in immunocompetent indi-
viduals, EBV is a cofactor rather than the driving influence
[10]. EBV likely exists as an episome with multiple copies
in the host cell, making it easier to detect than viruses
with one or few genomic copies per cell [12]. EBV epi-
somes have been employed to determine the association
of the virus with various aggressive types of lymphomas,
indicating that it is likely involved in tumor progression
but not tumor initiation, as might be assumed if present
in indolent tumors [11].
While it is clear that EBV contributes to the progression
of B-cell lymphoproliferative disease in immunosup-
pressed patients, its role in lymphomagenesis is less clear
in immunocompetent individuals [11]. However, the pres-
ence of viral genomes in these lymphomas offers interven-
tional targets and several approaches currently under
evaluation which include adoptive immunotherapy, inter-
feron, and small molecule targeting strategies in tumor
virus biology [7]. A sensitive and comprehensive pathogen
detection technology is critical to understand microbial
profiles associated with lymphomagenesis and their
contribution to the progression to high-grade lymphomas
[16]. Sequencing produces the most comprehensive and
unbiased information for microbial detection and dis-
covery when analyzing nucleic acids from uncharac-
terized samples, but high-throughput sequencing is
time-consuming and expensive [17]. PCR is a cheap, fast
and sensitive option, but it lacks the ability to detect the
existence of large numbers of organisms simultaneously
[18]. Microarray technology offers a reliable and sensitive
alternative to sequencing and PCR when analyzing or
screening tissue samples from patients with known or sus-
pected pathological conditions [18]. Moreover, microar-
rays are cheaper and faster than sequencing and permit
detection of multiple microbes in the same sample [19]. In
this study, we used the Lawrence Livermore MicrobialDetection Array (LLMDA), which is a pan-microbial
detection array capable of detecting all sequenced virus,
bacteria and plasmids, which uses a unique statistical
method, Composite Likelihood Maximization Method
for identifying multiple organisms in complex mixtures
[18-21]. The family-specific probes selected were con-
served enough to detect all known viral and bacterial
organisms while containing sufficient sequence vari-
ation for the detection of divergent species with homology
to sequenced organisms [22,23]. Our previous studies
have demonstrated the potential usage of the LLMDA
for detection of a broad spectrum of pathogens in a di-
verse set of clinical samples. We found that the microarray
technique can detect both DNA and RNA viruses that are
present in the same sample, as well as differentiate be-
tween different virus subtypes [18-20].
In this study we demonstrated the reliability of the
LLMDA technique in the detection of pathogen-associated
lymphoproliferative diseases. The LLMDA accurately iden-
tified EBV in EBV-positive samples and did not register
false positive results in EBV-negative samples. We de-
tected EBV in 5 out of 10 PTLD samples and showed that
EBV-positivity is usually correlated with aggressive stages
of lymphomas. We also demonstrated that the LLMDA can
also be applied to detect EBV in Formalin Fixed Paraffin
Embedded (FFPE) tissues which widens our sample pool
and improves selection of relevant samples. Our results
demonstrated that the LLMDA is a powerful tool for
analyzing and detecting known microbial pathogens in
lymphoproliferative disorders and potentially can be used
as a diagnostic tool or to provide a basis for potential tar-
geted and effective therapy regimens for these disorders.
Results
Detection of EBV in FFPE lymphoma samples
Though frozen tissue samples are ideal for nucleic acid
analysis, obtaining the requisite number of fresh frozen
samples can be challenging and is not always possible.
Therefore, we have explored the use of FFPE samples for
pathogen analysis. FFPE samples are in available abun-
dant supply since the advent and widespread use of tissue
banking, making them a good source for obtaining and
selecting adequate sample numbers for retrospective ana-
lysis. The LLMDA detected EBV in two of two EBV-
positive FFPE samples with 10 μm sections. The LLMDA
was able to detect EBV in all EBV-positive samples from
as little as 1 μm sections; and no false positives were regis-
tered (Figure 1 and Table 1). The Epstein–Barr virus
(EBV), also called human herpesvirus 4 (HHV-4), is a
virus of the herpes family. A case of NK/T cell lymphoma
was shown in Figure 2. The top matched genome se-
quence on the LLMDA is EBV B95-8. The human herpes-
virus 4 type 1 and GD1 also have the same log odds score,
a composite score to predict the probability of detection.
Figure 1 LLMDA’s detection of EBV in FFPE malignant lymphoma tissue from a 10 μm section with a 150 mm2 surface area. The
Epstein–Barr virus (EBV), also called human herpesvirus 4 (HHV-4). Array data was analyzed using the Composite Likelihood Maximization Method
developed at LLNL. The lighter and darker-colored portions of the bars represent the unconditional and conditional log-odds scores, respectively.
The conditional log-odds scores shows the contribution from a target that cannot be explained by another, more likely target above it, while the
unconditional score illustrates that some very similar targets share a number of probes. 20 out of the 24 probes specific for EBV were detected on
the LLMDA. The log odds score for EBV B95-8 genome is 107.9.
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detected, or 83% of EBV probes detected. The EBV status
was further confirmed by Epstein-Barr encoding region
(EBER) in situ hybridization (Figure 2). The second sam-
ple was a plasmablastic lymphoma (PBL) from an HIV+
patient where EBV was also detected by the LLMDA. The
results demonstrated that FFPE samples could be used
to reliably detect DNA sequences of known microbial
origin and could therefore also be used to study micro-
bial pathogen associations with lymphomas or other
tumors in general, opening a new potential discovery
tool for detection of previously unrecognized or novel
associations linking pathogens with oncogenesis. Add-
itionally, this technique can be used to assess for the per-
sistence of known viral pathogens in tissue samples from
patients who have undergone treatment to predict residual
disease (See Figure 3) (See Table 2).Table 1 Distribution of EBV-status of lymphoma cases in
the study
Type of tissue EBER positive/total
Benign lymphoid tissues 0/8
B-cell lymphomas 5/30
T-cell lymphomas 1/2
NK/T cell lymphomas 2/2
PTLDs 5/10
Hodgkin Lymphoma 1/6EBV screening of PTLD cases
PTLD is a heterogeneous group of disorders that develop
due to immunosuppressant regimens required for solid
organ transplant or bone marrow allograft [9]. The risk
for PTLD varies substantially depending on age, transplant
type, immunosuppressant therapy, and EBV status. PTLDs
are usually but not invariably associated with EBV. EBV
can only be detected in half of PTLD cases that develop
within a year of transplant [9,11,24]. The reported inci-
dence, however, of EBV-negative PTLDs varies widely,
and it is uncertain whether they should be considered
analogous to EBV-positive PTLDs and whether they have
any distinctive features [8]. We evaluated the accuracy of
LLMDA for detecting EBV in 10 PTLD cases (Figure 3).
DNA was isolated from the 10 frozen samples and applied
to the LLMDA. Our system accurately detected the
presence EBV in all the 5 EBV-positive cases which were
confirmed by EBER in situ hybridization and PCR ana-
lysis (data not shown), while no EBV sequence was de-
tected in all the 5-EBV-negative cases. These results show
that the LLMDA is capable of screening EBV-associated
PTLD cases.
Detection of EBV from different lymphoma types
Out of the 58 cases of lymphoid tissues analyzed by the
LLMDA, 5 out of the 30 B-cell lymphoma were positive
for EBV, all 5 were from aggressive types (21 aggressive
types vs 9 indolent types tested). All 9 of the indolent
B-cell lymphomas were negative for EBV by LLMDA.
Figure 2 Representative cases EBV positive malignant lymphoma detected by LLMDA in FFPE tissues. The assay can detect the very high
viral volume in plasmablastic lymphoma as well as relatively low viral volume in T-cell lymphoma.
Figure 3 Validation of the reliability of the LLMDA method for screening of monomorphic and classical Hodgkin lymphoma types of PTLD
lymphoma specimens. The LLMDA accurately detected the presence or absence of EBV in every case: 5 EBV-positive cases and 5-EBV-negative cases.
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Table 2 Analysis of post-transplant lymphoproliferative disorder (PTLD) cases using the LLMDA






1 Diffuse large B-cell lymphoma type PTLD, neck mass Yes 121.6 EBER+
2 Diffuse large B-cell lymphoma PTLD, liver Yes 114.7 EBER+
3 Diffuse large B-cell lymphoma type PTLD, spleen Yes 112.4 EBER+
4 Classical Hodgkin lymphoma, mixed cellularity type PTLD, neck lymph node Yes 104.4 EBER+
5 Extranodal NK/T cell lymphoma type PTLD, nasal mass Yes 87.1 EBER+
6 Burkitt lymphoma type PTLD, neck lymph node No NA EBER-
7 Diffuse large B-cell lymphoma type PTLD, brain mass No NA EBER-
8 Classical Hodgkin lymphoma, nodular sclerosis type PTLD, axillary lymph node No NA EBER-
9 Diffuse large B-cell lymphoma type PTLD, Inguinal lymph node No NA EBER-
10 Burkitt lymphoma type PTLD, neck mass No NA EBER-
The LLMDA accurately detected the presence or absence of EBV in 5 EBV-positive cases and 5-EBV-negative cases.
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tic T-cell lymphoma) was positive for EBV. Two out of two
NK/T cell lymphoma samples were positive for EBV. Eight
out of the eight specimens of control benign lymphoid tis-
sues were tested negative for EBV by LLMDA. Addition-
ally, only one of six classical Hodgkin lymphoma cases
was detected for EBV by LLMDA (Table 1).
Discussion
The link between pathogen infections and tumorigenesis
has been established in many cancers [2]. Virus-associated
cancers are on the rise worldwide due primarily to the
aging population as well as to the increasing use of solid
organ transplantation and the associated use of immuno-
suppressant drug regimens [7]. The identification of virus-
associated malignancies will provide researchers and
physicians with novel and effective therapeutic targets
and treatment options. There is a need to be able to accur-
ately and cost effectively screen increasing numbers of tu-
mors in order to identify their cause and develop effective
prevention and treatment options. The LLMDA is less ex-
pensive than sequencing per sample and provides far
greater flexibility than current sequencing and PCR diag-
nostic techniques [23]. Although the current study focuses
on EBV-associated cancers, the other viruses are also de-
tectable when present providing a “one test detects all”
technique.
Studying pathogen-induced tumorigenesis will require
access to large sample pools [7]. Therefore, studies using
frozen tissues come with limitations. Frozen tissues are
often in short supply, and it is difficult to obtain specific
tissues in significant numbers and in a timely fashion, as
researchers need them. On the other hand, FFPE tissues
are usually available in substantial numbers in many tissue
banks. We have confirmed the ability of the LLMDA sys-
tem to accurately detect EBV in FFPE samples. The option
to use FFPE provides researchers with the opportunity toscreen large collections of relevant tumor samples in ar-
chives worldwide, which is likely to reveal previously un-
known pathogen-associated malignancies. The technique
will also permit screening of samples from patients living
in geographic locations from which collection and proper
shipping of frozen tissues are prohibitive. The use of FFPE
samples could hasten the identification of pathogen-
induced malignancies and potentially help the develop-
ment of therapies for these diseases.
We have previously demonstrated that the array de-
tected viruses from a variety of human clinical samples
such as urine, feces, serum, skin lesion, cerebral spinal
fluid (CSF), tracheal aspirate, etc [18,19,21,25]. For ex-
ample, the microarray detected BK polyomavirus posi-
tive urine samples containing ≥1000 copies/mL (or an
equivalent of 5 viral copies in a Phi29-amplification reac-
tion) [18]. In another study, the array was used to detect
Kaposi-sarcoma associated herpes virus, or human herpes
virus 8 from bladder cancer samples. This further demon-
strated the potential of the microbial detection array tech-
nology to identify pathogens that might be linked to cancer
and other diseases. The array detected viral DNA from as
little as 20 fg or 100 genome copies input when combined
with whole genome amplification [18,20]. Therefore, this
microarray technique can be potentially used to detect
EBV infection in clinical samples including blood and
cerebral spinal fluid (CSF) [18-20,26].
Reliance on a technique as a clinical diagnostic tool re-
quires that its accuracy is tested and confirmed at a reli-
able level. In our study, the accuracy of the LLMDA has
been demonstrated by correctly identifying EBV in 5 out
of 10 PTLD clinically analyzed samples. Once the EBV’s
initial lytic infection is brought under control, it can per-
sist in latency. The EBV genome circularizes, resides in
the cell nucleus as an episome, and is copied by cellular
DNA polymerase. Each of the EBV latency programs
leads to the production of a limited, distinct set of viral
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EBER in situ hybridization is the standard methodology
of choice for the detection of the EBV in tissue sections
[16]. The large numbers of copies of EBERs can be de-
tected in latently infected cells. Positive studies show stain-
ing in the nuclei of the EBV-infected cells. False-negative
results by EBER in situ hybridization are most often due to
RNA degradation which still can be detected through the
LLMDA with advantage of multiple probes. The LLMDA
also possesses features unavailable to PCR and sequencing
as it can more easily detect multiple pathogens in the
same sample and this array also permits discovery of novel
pathogens. In addition, we find that EBV-infection was de-
tected from aggressive high grade lymphomas, but not the
indolent low grade lymphomas. These results support the
use of this system as a reliable clinical test for a variety of
other tumor types.
Conclusions
In the present study, we were able to successfully screen
FFPE lymphoma clinical cases, which will permit screening
of a large volume of relevant samples, found in the ar-
chives. We demonstrated the accuracy of the LLMDA sys-
tem by detecting the presence or absence of EBV in PTLD
cases by screening of clinical samples. Finally, we were able
to show that the system can replicate clinical results by
properly identifying EBV’s association with possible pro-
gression from indolent to aggressive tumor stages. Taken
together, our results support the use of the LLMDA as an
important clinical tool in the screening of pathogen-
associated lymphomas. In addition, this novel method has
the ability to detect multiple broad-spectrum pathogen
pathogens simultaneously [18].
In conclusion, using the LLMDA, we have developed
an accurate and sensitive method for screening frozen
and FFPE lymphoma samples. The technique performs
well in the testing of most cancer types; however PCR
and sequencing assays may be required to confirm re-
sults produced by the LLMDA for tumors containing
only a small percentage of transformed cells infected
with pathogen. Nevertheless, the LLMDA system may
provide a less expensive and/or more flexible clinical al-
ternative to current techniques with FISH, PCR analysis
and sequencing.
Methods
Patients and tissue specimens
A total of 58 patients (36 men and 22 women) diagnosed
with lymphoma were included in the study. The tissues
were collected at the Biorepository tissue bank, Department
of Pathology, of University of California, Davis Medical
Center during January 2010 to May 2014. The 10 PTLD
samples were collected in Loma Linda University Medical
Center. These cases previously had been diagnosed aslymphoma, and subclassified using standard morphologic
criteria, immunophenotyping, cytogenetic and selected
fluorescence in situ hybridization (FISH) studies. Part of
the fresh tissue samples was stored in liquid nitrogen until
the extraction of DNA. The remaining tissues were fixed
in formalin overnight. The study was approved by the IRB
Ethics Committee of UC Davis medical center and in-
formed consent was obtained.
DNA extraction
DNA was isolated from FFPE tissues using the AllPrep
DNA/RNA FFPE Kit (Qiagen) following the manufacturer’s
protocol with minor modifications. DNA was extracted
from 1, 2 or 4, 10 μm sections of 150 mm2 surface area.
Microarray analysis
Genomic DNA (gDNA) was isolated from frozen and FFPE
samples as described above. The gDNA was quantified
using a Qubit 2.0 Fluorometer (Life Technologies). Then,
1 μg gDNA was fluorescently labeled with Cy3-labeled ran-
dom nonamers using the NimbleGen One-Color Labeling
Kit (Roche). Labeled gDNA was re-quantitated with the
Qubit 2.0 Fluorometer and 2 μg of the labeled gDNA was
hybridized to the 12×135K format of the LLMDA v.5
for 60 hr. The arrays were washed using a NimbleGen
Wash Kit (Roche) and scanned at 532 nm (Cy3 chan-
nel) using the NimbleGen MS 200 Microarray Scanner
(Roche). The array was analyzed using the Composite
Likelihood Maximization method at the 99% threshold
(signal intensity of target probes were 99% above random
control probes) [17,25].
EBER in situ hybridization for Epstein-Barr virus
All cases were subjected to in situ hybridization using
oligonucleotides complementary to Epstein–Barr early
RNA (EBER) transcripts in paraffin embedded tissues
in an automated stainer (Integrated Oncology). The de-
tail testing protocols using EBER riboprobes has been
published [16].Abbreviations
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